CO4700448A1 - Composiciones farmaceuticas - Google Patents

Composiciones farmaceuticas

Info

Publication number
CO4700448A1
CO4700448A1 CO96029448A CO96029448A CO4700448A1 CO 4700448 A1 CO4700448 A1 CO 4700448A1 CO 96029448 A CO96029448 A CO 96029448A CO 96029448 A CO96029448 A CO 96029448A CO 4700448 A1 CO4700448 A1 CO 4700448A1
Authority
CO
Colombia
Prior art keywords
salts
pharmaceutically acceptable
pharmaceutical compositions
proteinase inhibitor
monoglyceride
Prior art date
Application number
CO96029448A
Other languages
English (en)
Inventor
Carole Anne Bailey
Josephine Christine Ferdinando
Navnit Shah
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO4700448A1 publication Critical patent/CO4700448A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición farmacéutica en dosis unitaria, que comprende:(a) una cantidad terapéuticamente efectiva de un inhibidor de proteinasa, sus sales o ésteres (incluyendo sus sales) aceptables desde el punto de vista farmacéutico; y (b) un portador aceptable desde el punto de vista farmacéutico que contiene un monoglicérido de ácidos grasos de cadena media en C8 -C10 , en donde el monoglicérido se encuentra presente en una cantidad que es suficiente para disolver el inhibidor de proteinasa.
CO96029448A 1995-06-06 1996-06-06 Composiciones farmaceuticas CO4700448A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46849395A 1995-06-06 1995-06-06

Publications (1)

Publication Number Publication Date
CO4700448A1 true CO4700448A1 (es) 1998-12-29

Family

ID=23860032

Family Applications (1)

Application Number Title Priority Date Filing Date
CO96029448A CO4700448A1 (es) 1995-06-06 1996-06-06 Composiciones farmaceuticas

Country Status (18)

Country Link
US (1) US6008228A (es)
KR (1) KR100267437B1 (es)
AR (1) AR002759A1 (es)
CO (1) CO4700448A1 (es)
EG (1) EG24294A (es)
HR (1) HRP960271B1 (es)
MA (1) MA23900A1 (es)
MY (1) MY116525A (es)
PE (1) PE4398A1 (es)
RO (1) RO115113B1 (es)
SA (1) SA96170162B1 (es)
SI (1) SI0831826T1 (es)
SV (1) SV1996000040A (es)
TW (1) TW452492B (es)
UA (1) UA44316C2 (es)
UY (1) UY24248A1 (es)
YU (1) YU49308B (es)
ZA (1) ZA964448B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9325445D0 (en) 1993-12-13 1994-02-16 Cortecs Ltd Pharmaceutical formulations
US5858401A (en) * 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
US6353538B1 (en) * 1999-05-13 2002-03-05 Intel Corporation Protective cover and packaging for multi-chip memory modules
US7527807B2 (en) 2000-06-21 2009-05-05 Cubist Pharmaceuticals, Inc. Compositions and methods for increasing the oral absorption of antimicrobials
US6248360B1 (en) 2000-06-21 2001-06-19 International Health Management Associates, Inc. Complexes to improve oral absorption of poorly absorbable antibiotics
AU2002230918B2 (en) * 2000-10-31 2006-12-14 Boehringer Ingelheim Pharmaceuticals, Inc. Oral self-emulsifying formulations of pyranone protease inhibitors
CA2477321A1 (en) * 2002-02-25 2003-08-28 Lyfjathroun Hf Absorption enhancing agent
US7157489B2 (en) * 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
BR0202252A (pt) * 2002-06-12 2004-06-29 Cristalia Prod Quimicos Farm Composição farmacêutica solúvel estável para administração de inibidores da hiv protease e processo de obtenção de composições farmacêuticas concentradas para a administração de inibidores da hiv protease
US6855332B2 (en) * 2002-07-03 2005-02-15 Lyfjathroun Hf. Absorption promoting agent
AU2004308712A1 (en) * 2003-12-23 2005-07-14 Tibotec Pharmaceuticals Ltd. Self-microemulsifying drug delivery systems of a HIV protease inhibitor
EP1877041A2 (en) * 2005-04-29 2008-01-16 Cubist Pharmaceuticals, Inc. Therapeutic compositions
US20100222311A1 (en) * 2007-10-19 2010-09-02 Purdue Research Foundation Solid formulations of crystalline compounds

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997851A (en) * 1987-12-31 1991-03-05 Isaacs Charles E Antiviral and antibacterial activity of fatty acids and monoglycerides
CA1340588C (en) * 1988-06-13 1999-06-08 Balraj Krishan Handa Amino acid derivatives
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
DE3919982A1 (de) * 1989-06-19 1990-12-20 Liedtke Pharmed Gmbh Orale lipidarzneiform
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
EP0448091B1 (en) * 1990-03-23 1998-08-05 The Green Cross Corporation Pharmaceutical composition containing slightly water-soluble drug
US5114957A (en) * 1990-05-08 1992-05-19 Biodor U.S. Holding Tocopherol-based antiviral agents and method of using same
CA2056911C (en) * 1990-12-11 1998-09-22 Yuuichi Nagano Hiv protease inhibitors
ATE183099T1 (de) * 1991-04-19 1999-08-15 Lds Technologies Inc Konvertierbare mikroemulsionsverbindungen
GB9113872D0 (en) * 1991-06-27 1991-08-14 Sandoz Ag Improvements in or relating to organic compounds
CN1071930A (zh) * 1991-07-10 1993-05-12 伊莱利利公司 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
US5516784A (en) * 1991-08-13 1996-05-14 Schering Corporation Anti-HIV (AIDS) agents
AU662434B2 (en) * 1992-08-07 1995-08-31 Sankyo Company Limited Peptides capable of inhibiting the activity of HIV protease, their preparation and their use
JPH08502492A (ja) * 1992-10-16 1996-03-19 スミスクライン・ビーチャム・コーポレイション 治療用ミクロエマルジョン
JPH08502490A (ja) * 1992-10-16 1996-03-19 スミスクライン・ビーチャム・コーポレイション 組成物
TW372972B (en) * 1992-10-23 1999-11-01 Novartis Ag Antiretroviral acyl compounds
US5538997A (en) * 1993-03-12 1996-07-23 Sandoz Ltd. 2,4-diamino-3-hydroxycarboxylic acid derivatives
US5318781A (en) * 1993-04-06 1994-06-07 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
SE9302135D0 (sv) * 1993-06-18 1993-06-18 Kabi Pharmacia Ab New pharmaceutical composition
IL110752A (en) * 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor

Also Published As

Publication number Publication date
UY24248A1 (es) 2000-12-29
HRP960271A2 (en) 1997-12-31
ZA964448B (en) 1996-12-06
RO115113B1 (ro) 1999-11-30
TW452492B (en) 2001-09-01
AR002759A1 (es) 1998-04-29
KR100267437B1 (ko) 2000-12-01
HRP960271B1 (en) 2002-02-28
MA23900A1 (fr) 1996-12-31
PE4398A1 (es) 1998-02-28
EG24294A (en) 2009-01-08
SI0831826T1 (en) 2003-02-28
SV1996000040A (es) 1997-03-19
US6008228A (en) 1999-12-28
MY116525A (en) 2004-02-28
YU49308B (sh) 2005-06-10
SA96170162B1 (ar) 2006-03-15
KR19990022425A (ko) 1999-03-25
YU33796A (sh) 1998-07-10
UA44316C2 (uk) 2002-02-15

Similar Documents

Publication Publication Date Title
CO4700448A1 (es) Composiciones farmaceuticas
ID30205A (id) Asam-asam lemak esensial dalam pencegahan kejadian-kejadian kardiovaskular
ES2191862T3 (es) Composicion liquida que comprende un inhibidor de la vih proteasa y un acido graso de c12-c18.
NO982161D0 (no) Administrasjonsmedia for analgetikum, antiinflammatoriske og antipyreticum legemidler som inneholder dinitrogenoksid og farmas÷ytiske sammensetninger som inneholder slike media og legemidler
NO975665D0 (no) Farmasöytisk sammensetning inneholdende en proteinaseinhibitor og et monoglyserid
RS52548B (en) ORAL DOSAGE FORM CONTAINED BY PDE 4 INHIBITOR AS ACTIVE INGREDIENT AND POLYVINYL PYRILIDONE AS EXPIENT
NZ217703A (en) 2-(2-fluoro-4-biphenylyl) propionic acid compositions
RS49602B (sr) Farmaceutske mikrosfere valproinske kiseline za oralnu upotrebu
CO5550418A2 (es) Formulaciones antihistaminicas para formas de dosificacion de capsula blanda
JPS5791913A (en) Pharmaceutical preparation of drug
ES8205394A1 (es) Procedimiento para preparar esteres de l-arginina en solu- cion acuosa
KR880010762A (ko) 소화성궤양의 치료방법 및 치료용 합성물(Composition and Method for Treatment of peptic Ulcers)
ES2141049B1 (es) Formulaciones farmaceuticas en aerosol que contienen trigliceridos de cadena media como surfactantes.